Fabio Cataldi - Feb 29, 2024 Form 4 Insider Report for Landos Biopharma, Inc. (LABP)

Role
Chief Medical Officer
Signature
/s/ Gregory Oakes, Attorney-in-Fact
Stock symbol
LABP
Transactions as of
Feb 29, 2024
Transactions value $
$0
Form type
4
Date filed
3/4/2024, 04:14 PM
Previous filing
Mar 2, 2023
Next filing
May 23, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LABP Restricted Stock Unit Award $0 +21.1K $0.00 21.1K Feb 29, 2024 Common Stock 21.1K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents the right to receive one share of Landos Biopharma, Inc., Inc. common stock.
F2 The Restricted Stock Unit ("RSU") shall vest as to 66 2/3% of the shares underlying the RSU on the second anniversary of the date of grant and shall vest as to 33 1/3% of the shares underlying the RSU on the third anniversary of the date of grant, subject to the Reporting Person's continuous service with the Issuer on each such date.